These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28688917)

  • 1. Real-World Economic Burden Associated with Transplantation-Related Complications.
    Perales MA; Bonafede M; Cai Q; Garfin PM; McMorrow D; Josephson NC; Richhariya A
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1788-1794. PubMed ID: 28688917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
    Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
    J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of second allogeneic hematopoietic cell transplantation.
    Khera N; Storer B; Sandmaier BM; Chapko MK; Lee SJ
    Transplantation; 2013 Jul; 96(1):108-15. PubMed ID: 23694949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.
    Maziarz RT; Devine S; Garrison LP; Agodoa I; Badaracco J; Gitlin M; Perales MA
    Transplant Cell Ther; 2023 Oct; 29(10):637.e1-637.e9. PubMed ID: 37364775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
    Bonafede M; Anaissie E; Evans K; Itzler R
    BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation.
    Peffault De Latour R; Chevallier P; Blaise D; Alami S; Lévy-Bachelot L; Allavoine T; Tadmouri A; Blomkvist J; Duhamel A; Srour M; Beauvais D; Yakoub-Agha I
    J Med Virol; 2020 Dec; 92(12):3665-3673. PubMed ID: 32297984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Body Composition Following Autologous and Allogeneic Hematopoietic Cell Transplantation: Incidence of Sarcopenia and Association with Clinical Outcomes.
    DeFilipp Z; Troschel FM; Qualls DA; Li S; Kuklinski MW; Kempner ME; Hochberg E; Chen YB; El-Jawahri A; Fintelmann FJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1741-1747. PubMed ID: 29496561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
    Htut M; D'Souza A; Krishnan A; Bruno B; Zhang MJ; Fei M; Diaz MA; Copelan E; Ganguly S; Hamadani M; Kharfan-Dabaja M; Lazarus H; Lee C; Meehan K; Nishihori T; Saad A; Seo S; Ramanathan M; Usmani SZ; Gasparetto C; Mark TM; Nieto Y; Hari P
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):478-485. PubMed ID: 29079457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
    Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.
    Dhakal B; Giri S; Levin A; Rein L; Fenske TS; Chhabra S; Shah NN; Szabo A; D'Souza A; Pasquini M; Hari P; Hamadani M
    JAMA Netw Open; 2019 Jul; 2(7):e196476. PubMed ID: 31276175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
    McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
    Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study.
    Rangarajan HG; Smith LC; Stanek JR; Hall M; Abu-Arja R; Auletta JJ; O'Brien SH
    Biol Blood Marrow Transplant; 2019 May; 25(5):1031-1038. PubMed ID: 30625391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
    Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
    Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis.
    Johnson BH; Taylor A; Kim G; Drahos J; Yang J; Akbari M; Shah NN
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):834-841. PubMed ID: 30625389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.
    Majhail NS; Mau LW; Denzen EM; Arneson TJ
    Bone Marrow Transplant; 2013 Feb; 48(2):294-300. PubMed ID: 22773126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation.
    Bansal R; Park H; Taborda CC; Gordillo C; Mapara MY; Assal A; Uhlemann AC; Reshef R
    Transplant Cell Ther; 2022 Mar; 28(3):135-144. PubMed ID: 34958974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
    El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
    JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study.
    Sharafeldin N; Bosworth A; Patel SK; Chen Y; Morse E; Mather M; Sun C; Francisco L; Forman SJ; Wong FL; Bhatia S
    J Clin Oncol; 2018 Feb; 36(5):463-475. PubMed ID: 29252122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.